Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

  Names of reporting persons

   Takeda Pharmaceutical Company Limited

  Check the appropriate box if a member of a group (see instructions)

  (a)  ☐        (b)  ☐

  SEC use only

  Citizenship or place of organization

  Japan

Number of

shares

  beneficially  

owned by

each

reporting

person

with:

  Sole voting power

  0

  Shared voting power

  2,679,802

  Sole dispositive power

  0

  Shared dispositive power

  2,679,802

  Aggregate amount beneficially owned by each reporting person

  2,679,802 ⁽¹⁾

  Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

  ☐

  Percent of class represented by amount in Row (9)

  9.9%⁽²⁾

  Type of reporting person (see instructions)

  CO

Takeda Pharmaceutical Company Limited’s beneficial ownership of the issuer’s Common Stock is comprised of 2,679,802 shares of Common Stock held by Takeda Ventures, Inc., a wholly-owned indirect subsidiary of Takeda Pharmaceutical Company Limited. Takeda Ventures, Inc. is owned directly by Takeda Pharmaceuticals U.S.A., Inc., which is owned directly by both Takeda Pharmaceutical Company Limited (58.09%) and Takeda Pharmaceuticals International AG (41.91%). Takeda Pharmaceuticals International AG is a wholly-owned direct subsidiary of Takeda Pharmaceutical Company Limited.

Based on 26,829,689 shares of Common Stock outstanding after the issuer’s initial public offering, as disclosed in the issuer’s final prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, dated May 8, 2019 (the “Final Prospectus”), and rounded from 9.988%. The number of shares includes the additional 661,800 shares that the underwriters purchased pursuant to an option, as stated in a Form 8-K filed by the issuer on May 13, 2019 (the “Form 8-K”).

  Names of reporting persons

  Takeda Pharmaceuticals International AG

  Check the appropriate box if a member of a group (see instructions)

  (a)  ☐        (b)  ☐

  SEC use only

  Citizenship or place of organization

  Switzerland

Number of

shares

  beneficially  

owned by

each

reporting

person

with:

  Sole voting power

  0

  Shared voting power

  1,123,105 ⁽¹⁾

  Sole dispositive power

  0

  Shared dispositive power

  1,123,105⁽¹⁾

  Aggregate amount beneficially owned by each reporting person

  1,123,105 ⁽¹⁾

  Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

  ☐

  Percent of class represented by amount in Row (9)

  4.2%⁽²⁾

  Type of reporting person (see instructions)

  CO

Takeda Pharmaceuticals International AG’s beneficial ownership of the issuer’s Common Stock is comprised of 1,123,105 of the 2,679,802 shares of Common Stock held by Takeda Ventures, Inc., an indirect subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG owns 41.91% of Takeda Pharmaceuticals U.S.A., Inc. and Takeda Ventures, Inc. is a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc.

Based on 26,829,689 shares of Common Stock outstanding after the issuer’s initial public offering, as disclosed in the issuer’s Final Prospectus, including the additional 661,800 shares that the underwriters purchased pursuant to an option as stated in the Form 8-K.

  Names of reporting persons

  Takeda Pharmaceuticals U.S.A., Inc.

  Check the appropriate box if a member of a group (see instructions)

  (a)  ☐        (b)  ☐

  SEC use only

  Citizenship or place of organization

  United States

Number of

shares

  beneficially  

owned by

each

reporting

person

with:

  Sole voting power

  0

  Shared voting power

  2,679,802

  Sole dispositive power

  0

  Shared dispositive power

  2,679,802

  Aggregate amount beneficially owned by each reporting person

  2,679,802 ⁽¹⁾

  Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

  ☐

  Percent of class represented by amount in Row (9)

  9.9%⁽²⁾

  Type of reporting person (see instructions)

  CO

Takeda Pharmaceuticals U.S.A., Inc.’s beneficial ownership of the issuer’s Common Stock is comprised of 2,679,802 shares of Common Stock held by Takeda Ventures, Inc., a wholly-owned direct subsidiary of Takeda Pharmaceuticals U.S.A., Inc.

Based on 26,829,689 shares of Common Stock outstanding after the issuer’s initial public offering, as disclosed in the issuer’s Final Prospectus, including the additional 661,800 shares that the underwriters purchased pursuant to an option as stated in the Form 8-K, and rounded from 9.988%.

  Names of reporting persons

  Takeda Ventures, Inc.

  Check the appropriate box if a member of a group (see instructions)

  (a)  ☐        (b)  ☐

  SEC use only

  Citizenship or place of organization

  United States

Number of

shares

  beneficially  

owned by

each

reporting

person

with:

  Sole voting power

  0

  Shared voting power

  2,679,802

  Sole dispositive power

  0

  Shared dispositive power

  2,679,802

  Aggregate amount beneficially owned by each reporting person

  2,679,802

  Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

  ☐

  Percent of class represented by amount in Row (9)

  9.9%⁽¹⁾

  Type of reporting person (see instructions)

  CO

Based on 26,829,689 shares of Common Stock outstanding after the issuer’s initial public offering, as disclosed in the issuer’s Final Prospectus, including the additional 661,800 shares that the underwriters purchased pursuant to an option as stated in the Form 8-K, and rounded from 9.988%.

Name of issuer:

Address of issuer’s principal executive offices:

Name of person filing:

Address of principal business office or, if none, residence:

Citizenship:

Title of class of securities:

CUSIP No.:

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Ownership

Ownership of 5 Percent or Less of a Class.

Ownership of More than 5 Percent on Behalf of Another Person.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Identification and Classification of Members of the Group.

Notice of Dissolution of Group.

Certifications